SCHEMBL19880314

SCHEMBL19880314

CC(C)C(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)OC2C1OC(=S)n1ccnc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 3/20 0.42
▸ PDE4D Q08499 3/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ HTR1A P08908 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ ADRB3 P13945 1/20 0.42
▸ PTGS2 P35354 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ RXFP1 Q9HBX9 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PDE4B Q07343 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ ADORA1 P30542 7/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10459778 1.00 PDE4A (0.42) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL10457978 0.90 PRMT6 (0.42) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL19880312 0.87 ALDH1A1 (0.44) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL10458995 0.87 ALDH1A1 (0.44) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL20346094 0.87 PDE4A (0.41) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL10457913 0.87 PDE4A (0.41) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL10459452 0.83 PDE4A (0.49) PDE4APDE4DLMNARXFP1NPSR1
SCHEMBL19880326 0.83 PDE4A (0.49) PDE4APDE4DLMNARXFP1NPSR1
SCHEMBL25966452 0.78 PRMT6 (0.42) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL10457977 0.78 PRMT6 (0.40) PDE4APDE4DCYP1A2HTR1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2020-03-24 — — US disclosed
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 — — US disclosed
US-9896472-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2018-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT PDE4A 3652/4885PDE4D 4148/4885CYP1A2 4749/4885
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis NSUN2, RNGTT, RNMT PDE4A 3652/4885PDE4D 4148/4885CYP1A2 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback